MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
16.29
-0.06 (-0.37%)
Aug 18, 2026, 1:12 PM EDT - Market open

MLTX Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
46.9641.9730.3222.3223.0121.66
Research & Development
221.38202.86112.7731.842.0512.64
Operating Expenses
268.34244.83143.0954.1265.0634.29
Operating Income
-268.34-244.83-143.09-54.12-65.06-34.29
Interest Expense
-10.09-7.25----
Currency Exchange Gain (Loss)
0.020.60.040.150.33-0.07
Other Non Operating Income (Expenses)
14.2621.7722.099.990.27-0
EBT Excluding Unusual Items
-264.15-229.71-120.96-43.99-64.47-34.37
Other Unusual Items
------30
Pretax Income
-264.15-229.71-120.96-43.99-64.47-64.37
Income Tax Expense
1.080.610.280.090.040.01
Earnings From Continuing Operations
-265.22-230.32-121.24-44.08-64.51-64.37
Minority Interest in Earnings
1.5632.318.0714.53-
Net Income
-263.67-227.32-118.94-36.01-49.97-64.37
Net Income to Common
-263.67-227.32-118.94-36.01-49.97-64.37
Net Income Growth
------
Shares Outstanding (Basic)
69646349298
Shares Outstanding (Diluted)
69646349298
Shares Change
9.53%2.54%27.99%67.30%274.47%-
EPS (Basic)
-3.81-3.53-1.89-0.73-1.70-8.21
EPS (Diluted)
-3.81-3.53-1.89-0.73-1.70-8.21
EPS Growth
------
Free Cash Flow
-225.18-196.04-117.11-43.06-55.91-42.27
Free Cash Flow Per Share
-3.26-3.04-1.86-0.88-1.90-5.39
EBITDA
-265.1-242.22-141.71-53.75-64.9-34.29
D&A For EBITDA
3.242.621.390.370.160.01
EBIT
-268.34-244.83-143.09-54.12-65.06-34.29
SEC Filings: 10-K · 10-Q